Population pharmacokinetics of anidulafungin in critically ill patients

S. Luque, W. Hope, N. Campillo, R. Muñoz-Bermúdez, L. Sorli, J. Barceló-Vidal, E. González-Colominas, F. Alvarez-Lerma, J. R. Masclans, M. Montero, J. P. Horcajada, S. Graua

Producción científica: Contribución a una revistaArtículoInvestigación

15 Citas (Scopus)

Resumen

A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.
Idioma originalInglés
Número de artículoe00378-19
PublicaciónAntimicrobial Agents and Chemotherapy
Volumen63
N.º7
DOI
EstadoPublicada - jul 2019

Huella

Profundice en los temas de investigación de 'Population pharmacokinetics of anidulafungin in critically ill patients'. En conjunto forman una huella única.

Citar esto